Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.

Abstract

Teicoplanin in a 400 mg intravenous loading dose followed by 200 mg/day intravenously or intramuscularly was given to 19 patients with deep-seated staphylococcal infections. Only eight patients (44.4%) were considered cured, failure mostly being observed in patients with osteomyelitis, endocarditis and bacteremia. Poor tissue kinetics of teicoplanin and the presence of foreign bodies are probable explanations for the reported failures. Future trials using a higher dose of teicoplanin with or without the addition of rifampicin or gentamicin seem to be justified.

• Authors: N Galanakis, H Giamarellou, N Vlachogiannis, C Dendrinos, G K Daikos
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 7 Issue 2 Pg. 130-4 (Apr 1988) ISSN: 0934-9723 [Print] Germany
• PMID: 2968907 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Glycopeptides
• Teicoplanin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, pharmacokinetics, therapeutic use)
• Endocarditis, Bacterial (drug therapy)
• Female
• Foreign Bodies (complications)
• Glycopeptides (administration & dosage, pharmacokinetics, therapeutic use)
• Humans
• Injections, Intramuscular
• Injections, Intravenous
• Male
• Middle Aged
• Osteomyelitis (drug therapy)
• Sepsis (drug therapy)
• Staphylococcal Infections (complications, drug therapy)
• Teicoplanin